当前位置: X-MOL 学术J. Hematol. Oncol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Immunosuppressive tumor microenvironment and immunotherapy of hepatocellular carcinoma: current status and prospectives
Journal of Hematology & Oncology ( IF 29.5 ) Pub Date : 2024-04-29 , DOI: 10.1186/s13045-024-01549-2
Ke-Yu Shen 1, 2 , Ying Zhu 1, 2 , Sun-Zhe Xie 1, 2 , Lun-Xiu Qin 1, 2
Affiliation  

Hepatocellular carcinoma (HCC) is a major health concern worldwide, with limited therapeutic options and poor prognosis. In recent years, immunotherapies such as immune checkpoint inhibitors (ICIs) have made great progress in the systemic treatment of HCC. The combination treatments based on ICIs have been the major trend in this area. Recently, dual immune checkpoint blockade with durvalumab plus tremelimumab has also emerged as an effective treatment for advanced HCC. However, the majority of HCC patients obtain limited benefits. Understanding the immunological rationale and exploring novel ways to improve the efficacy of immunotherapy has drawn much attention. In this review, we summarize the latest progress in this area, the ongoing clinical trials of immune-based combination therapies, as well as novel immunotherapy strategies such as chimeric antigen receptor T cells, personalized neoantigen vaccines, oncolytic viruses, and bispecific antibodies.

中文翻译:


肝细胞癌免疫抑制肿瘤微环境及免疫治疗:现状与展望



肝细胞癌 (HCC) 是世界范围内的主要健康问题,治疗选择有限且预后不良。近年来,免疫检查点抑制剂 (ICI) 等免疫疗法在 HCC 的全身治疗中取得了长足的进步。基于 ICI 的联合治疗一直是该领域的主要趋势。最近,durvalumab 加 tremelimumab 的双重免疫检查点阻断也已成为晚期 HCC 的有效治疗方法。然而,大多数 HCC 患者获得的好处有限。了解免疫学原理并探索提高免疫疗法疗效的新方法已引起广泛关注。在本综述中,我们总结了该领域的最新进展、正在进行的免疫联合疗法临床试验,以及嵌合抗原受体 T 细胞、个性化新抗原疫苗、溶瘤病毒和双特异性抗体等新型免疫治疗策略。
更新日期:2024-04-29
down
wechat
bug